Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.
This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
1. Title of Book - p. ii 2. Cover image - p. ii 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. i 6. Copyright - p. i 7. Cover Image Insert - p. i 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. i 9. About the Series Editor - p. ix 10. Aims and Scope of Volume - p. x 11. About the Volume Editor - p. x 12. Preface - p. x 13. Contributors - p. x 14. Chapter 1. The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions - p. 13 15. ALK rearranged lung cancer: TKI treatment and outcome - p. 31 16. Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC - p. 57 17. Chapter 4. Management of ALK positive patients with tumors other than lung cancer - p. 71 18. Chapter 5. Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance - p. 87 19. Chapter 6. Resistance mechanisms to ALK TKIs in tumors other than lung cancer - p. 104 20. Chapter 7. Therapeutic strategies to overcome ALK resistance in lung cancer - p. 123 21. Chapter 8. Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL - p. 141 22. Chapter 9. Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma - p. 161 23. Chapter 10. State of the art and future perspectives - p. 177 24. Index - p. 191
Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.
This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.
1. Title of Book - p. ii 2. Cover image - p. ii 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. i 6. Copyright - p. i 7. Cover Image Insert - p. i 8. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. i 9. About the Series Editor - p. ix 10. Aims and Scope of Volume - p. x 11. About the Volume Editor - p. x 12. Preface - p. x 13. Contributors - p. x 14. Chapter 1. The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions - p. 13 15. ALK rearranged lung cancer: TKI treatment and outcome - p. 31 16. Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC - p. 57 17. Chapter 4. Management of ALK positive patients with tumors other than lung cancer - p. 71 18. Chapter 5. Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance - p. 87 19. Chapter 6. Resistance mechanisms to ALK TKIs in tumors other than lung cancer - p. 104 20. Chapter 7. Therapeutic strategies to overcome ALK resistance in lung cancer - p. 123 21. Chapter 8. Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK + ALCL - p. 141 22. Chapter 9. Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma - p. 161 23. Chapter 10. State of the art and future perspectives - p. 177 24. Index - p. 191
